MIAMI– Seventy percent (70%) of respondents to an international survey conducted earlier this year said they are either “bothered” or “really bothered” when tobacco companies make money from an inhaler, medication, or other devices that treat their lung conditions. The findings are available in a newly published communications brief, “Tobacco industry ownership of pharmaceutical companies: an international survey of people with respiratory disease,” in the Journal Thorax, the official journal of the British Thoracic Society.
The survey gave people with chronic lung disease a voice in the conversation about tobacco corporations owning companies that develop tools and medications to treat lung conditions. A total of 1,196 people who reported inhaler use completed the survey in early 2022. Based on the survey’s findings, as reported in Thorax, most patients care deeply that tobacco companies have a financial stake in drug or device companies and profit from life-saving treatment.
The COPD Foundation partnered with Global Allergy and Airways Patient Platform (GAAPP) and Lung Foundation Australia to conduct the survey among people with chronic lung diseases in English, Spanish, and German between January and March of 2022. All responses remained confidential; no personally identifiable information was collected. Among the respondents, most (68%) were from North America, although broader global regions were represented. Also, most respondents were former smokers (73%), with 11% reporting current smoking and 15% reporting they never smoked.
After Philip Morris International (PMI) acquired pharmaceutical company Vectura in 2021, patient advocacy groups wanted to understand patients’ attitudes toward tobacco organizations’ stake in the companies that make their respiratory inhaler devices. Vectura develops several widely used medical delivery devices and/or formulations for inhaled therapies used in people with chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma.
“We joined an array of global patient advocacy groups, academic organizations, and concerned individuals in protesting the sale of Vectura to PMI,” said Ruth Tal-Singer, PhD, President & CEO of the COPD Foundation, and co-author of the Thorax brief. “And, as we noted in Thorax, the purchase of Vectura led to medical societies prohibiting the organization’s participation in conferences and publications.”
Tal-Singer explained that the missing piece in the global advocacy effort was the patient voice – and the Foundation saw it as critical to the conversation.
Linda Walsh, Chief Community Engagement Officer, discussed the idea for an international patient survey with the Foundation’s COPD360 Community Engagement Committee (COPD360CEnCo), comprised of patients and caregivers.
“The vision was to obtain a diverse point of view from a minimum of 1,000 respondents with different lung conditions,” Walsh said. “Our community was fully supportive of the survey. After all, the patient voice is at the core of our mission at the Foundation. Empowering patients to share their lived experiences with lung diseases allows us to focus research and innovation on what matters most so we can create breakthroughs in how chronic lung conditions are treated. When an overwhelming majority of patients demand transparency and ethically funded treatment options, then we must elevate their voices to a level that creates lasting and meaningful change,” she added.
